Ashland to present research on key challenges in pharmaceutical formulation development
(Thomson Reuters ONE) -
WILMINGTON, Del. - Ashland Specialty Ingredients, a commercial unit of Ashland
Inc. (NYSE: ASH), today announced that it will present new research on
excipients and tablet coatings at the American Association of Pharmaceutical
Scientists Annual Meeting and Exposition (AAPS) in Washington, DC, Oct. 23-27.
The research, which includes solutions for enhancing drug solubility,
formulating controlled-release systems, improving tablet properties and reducing
costs, is based on recent studies conducted by Ashland researchers.
Ashland Specialty Ingredients was formed in August when Ashland completed its
acquisition of International Specialty Products (ISP) Inc. and combined it with
its Functional Ingredients business. Together, Ashland scientists focus on
advancing active pharmaceutical ingredient (API) delivery, protection and
solubility through a dynamic excipient portfolio.
As a result of high-throughput screening and rational drug design, formulators
today are identifying a larger number of drug candidates with poor solubility
during the discovery process. Reportedly as many as 60 percent of drugs in
development have issues related to poor solubility. Ashland scientists will
publish results of studies on emerging solid-dispersion technology, using spray
drying and hot-melt extrusion to improve solubility, bioavailability and
stability of poorly soluble drugs using Klucel(TM) hydroxypropylcellulose (HPC),
Plasdone(TM) povidone and Plasdone copovidone.
In one study, Ashland scientists were able to reduce the dosing regimen of an
API from sixteen capsules to one tablet in a clinical trial using screening
techniques to quickly select the optimum polymer and polymer level for stable,
amorphous solid dispersions with the largest dissolution enhancement. This is
one example of how Ashland's products and knowledge help bring new products to
market, reduce development times and product costs.
As hot-melt extrusion is gaining popularity for solubilization of insoluble
drugs, twin-screw extrusion is also gaining attention as a continuous
alternative to traditional high-shear granulation. This continuous process
enables faster through-put and easier scale-up, which translates to cost
savings. Ashland will present results on how Klucel HPC,Plasdone povidone, and
Benecel(TM) hypromellose (HPMC) perform in continuous low-temperature extrusion
granulation as compared to traditional wet granulation. The results show twin-
screw extrusion as a promising cost saving method for high-dose formulations and
highlight how tablets made via extrusion showed improved strength and low
friability compared to traditional wet granulation.
Ashland scientists will be present during the technical posters sessions as well
as at Booths 519 and 1229 to answer questions pertaining to the 20 contributed
papers:
Monday - Oct. 24, (1 - 5 p.m.)
* Poster M1070 - An examination of the use of high-solids film-coating systems
as a means of reducing the costs of aqueous coating processes
* Poster M1074 - The application of an aqueous high-solids coatings system at
low bed temperatures
* Poster M1107- Effect of spray-drying process parameters on solid dispersion
powder properties
* Poster M1108 - Effect of solution and polymer properties on solid dispersion
powder properties
* Poster M1109 - Effect of scale-up from laboratory to clinical-scale spray
dryer on solid dispersion powder properties
* Poster M1384 - Effect of super-disintegrants on compactability/ bondability
of tablet fillers
Tuesday - Oct. 25, (1 - 5 p.m.)
* Poster T3277 - Tablets manufactured via HME as a processing technique for
solubility enhancement: stability assessment and in vitro release comparison
to a marketed formulation
* Poster T3285 - Use of a compaction simulator to compare the compaction
behavior of dry binders in model pharmaceutical formulations
* Poster T3282 - The effect of moisture barrier film coating and packaging
selection on moisture sensitive multivitamin tablets
Wednesday - Oct. 26
* Poster W4226 (8 a.m. - noon) - Taste masking performance of two grades of
Hydroxypropylcellulose melt extruded pellets
* Poster W4237 (8 a.m. - noon) - Preparation and characterization of solid
dispersion tablets of Efavirenz with Benecel(TM) E5 PH
* Poster W4350 (8 a.m. - noon) - Polymer selection and optimization in
development of a spray-dried dispersion with enhanced bioavailability
* Poster W4238 (8 a.m. - noon) - Characterization of hot-melt extruded
immediate-release solid dosage forms with cellulose either polymers for a
poorly soluble drug
* Poster W4248 (8 a.m. - noon) - Continuous twin-screw extrusion granulation
using HPC as a binder
* Poster W5172 (1 - 5 p.m.) - Erosion and dissolution performance of
intermediate molecular weight HPMC controlled-release polymers
* Poster W5227 (1 - 5 p.m.) - In vitro evaluation of Hydroxypropylcellulose
immediate-release tablets produced by melt extrusion technology
* Poster W5259 (1 - 5 p.m.) - Process development and analysis of hot-melt
extrudates with enhanced solubility
Thursday - Oct. 27, (8 a.m. - noon)
* Poster R6168 - Characterization of hot-melt extruded immediate-release solid
dosage forms with cellulose ether polymers for a poorly soluble drug
* Poster R6279 - Ethylcellulose and Hydroxypropylcellulose as rate-controlling
polymers for hot-melt extrusion of highly soluble drugs
For more information about the papers Ashland has contributed to AAPS, contact
Ann Druffner in Wayne, N.J. Telephone: (973) 628-4103.
Delivering pharmaceutical and nutraceutical performance since the 1950s, Ashland
creates value for its customers through applications knowledge, regulatory
support and a powerful product portfolio:
* Aquarius(TM) and Advantia(TM) coating systems
* Aqualon(TM) ethylcellulose
* Aqualon(TM) and Blanose(TM) sodium carboxymethylcellulose
* Benecel(TM) methylcellulose and hypromellose
* Klucel(TM) hydroxypropylcellulose
* Natrosol(TM) hydroxyethylcellulose
* Plasdone(TM) povidone
* Plasdone(TM) copovidone
* Polyplasdone(TM) crospovidone
Ashland Specialty Ingredients offers industry-leading products, technologies and
resources for solving formulation and product performance challenges in key
markets including personal care, pharmaceutical, food and beverage, coatings and
energy. Using natural, synthetic and semi-synthetic polymers derived from plant
and seed extract, cellulose ethers and vinyl pyrrolidones, Ashland Specialty
Ingredients offers comprehensive and innovative solutions for today's demanding
consumer and industrial applications.
In more than 100 countries, the people of Ashland Inc. (NYSE: ASH) provide the
specialty chemicals, technologies and insights to help customers create new and
improved products for today and sustainable solutions for tomorrow. Our
chemistry is at work every day in a wide variety of markets and applications,
including architectural coatings, automotive, construction, energy, food and
beverage, personal care, pharmaceutical, tissue and towel, and water treatment.
Visit www.ashland.com to see the innovations we offer through our four
commercial units - Ashland Specialty Ingredients, Ashland Water Technologies,
Ashland Performance Materials and Ashland Consumer Markets (Valvoline).
- 0 -
(TM)Trademark of Ashland or its subsidiaries, registered in various countries
FOR FURTHER INFORMATION:
Media Relations
Ken Gordon
614-790-1832
kdgordon(at)ashland.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ashland Inc. via Thomson Reuters ONE
[HUG#1554420]
Unternehmensinformation / Kurzprofil:
Datum: 13.10.2011 - 13:18 Uhr
Sprache: Deutsch
News-ID 75903
Anzahl Zeichen: 9117
contact information:
Town:
Covington
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 196 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ashland to present research on key challenges in pharmaceutical formulation development"
steht unter der journalistisch-redaktionellen Verantwortung von
Ashland Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
